A placebo controlled clinical trial on the efficacy of atorvastatin 20 mg daily in patients with bronchial hyper-responsiveness.

A placebo controlled clinical trial on the efficacy of atorvastatin 20 mg daily administration for 4-6 weeks in patients with bronchial hyper-responsiveness.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000704291

Enrollment

Registered

2009-08-14

Start date

2008-10-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

We could not find any study that has examined the use of atorvastatin in bronchial hyperresponsiveness . The proposed study will provide scientifically valid data to date on whether atorvastatin 20 mg is effective in bronchial hyperresponsiveness or not

Interventions

Atorvastatin 20mg once daily will be administered orally for 4-6 weeks to all patients in the intervention group according to the clinician's discretion.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

16 Years to 65 Years

Healthy volunteers

Inclusion criteria

Patients present with cough for more than 6 weeks.

Exclusion criteria

Patients who had contraindication for methacoline challenge test (according to American Thoracic Society/European Respiratory Society -ATS/ERS- guideline 2006)/ patient with previous diagnosis of asthma/patients who suffer heart failure/ obvious paroxysmal nocturnal dyspnea (PND) or wheezing in physical exam.

Outcome results